AMPKbeta subunits, more than just a scaffold in the formation of AMPK complex by Sanz, Pascual et al.
1 
 
AMPKbeta subunits, more than just a scaffold in the formation of AMPK 
complex 
 
Sanz, P*, Rubio, T and Garcia-Gimeno, M.A. 
 
Instituto de Biomedicina de Valencia, CSIC and Centro de Investigación en Red 
de Enfermedades Raras (CIBERER), Jaime Roig 11, 46010-Valencia, Spain. 
 
*Corresponding author: Dr. Pascual Sanz, Instituto de Biomedicina de 
Valencia, CSIC, Jaime Roig 11, 46010-Valencia, Spain. Tel: +34963391779; 
FAX: +34963690800;  
e-mail: sanz@ibv.csic.es 
 
Running Title: AMPK subunits regulate AMPK activity 
 
Abbreviations: AMPK, AMP-activated protein kinase; -SBS, -subunit 
binding sequence; CIDEA, cell-death-inducing DFFA-like effector A; CBM, 
carbohydrate binding module; CBS, cystathionine-beta-synthase; DUB, 
deubiquitinating enzyme; PIASy, protein inhibitor of activated STAT; SENP, 
sentrin-specific protease (desumoylating enzyme); SUMO, small ubiquitin-like 
modifier. 
 
Keywords: AMPK, CBM, phosphorylation, myristoylation, ubiquitination, 
sumoylation, activators. 
2 
 
ABSTRACT 
AMP-activated protein kinase (AMPK) is a sensor of energy status composed of 
a catalytic subunit (AMPK), a scaffolding subunit (AMPK) and a regulatory 
subunit involved in nucleotide binding (AMPK). Activation of AMPK results in 
enhancement of catabolic processes and downregulation of anabolic pathways 
with the aim to equilibrate the energy status of the cell. The study of the 
regulation of the activity of the AMPK complex has been traditionally focused on 
modifications of AMPK and AMPK subunits by post-translational changes (i.e. 
phosphorylation of the catalytic subunit) and allosteric activation by AMP. In this 
review we summarize recent reports that indicate that AMPK subunits are also 
critical players in AMPK function, since they can regulate the phosphorylation 
status and activity of the AMPK complex. AMPK1- and AMPK2-containing 
complexes differ in their capacity to be activated by specific drugs (i.e., 
A769622, salicylate) and also by the ability to undergo post-translational 
modifications. This selective behavior opens the possibility to design specific 
drugs that activate AMPK complexes containing specific -isoforms. 
 
INTRODUCTION 
AMP-activated protein kinase (AMPK) is a sensor of energy status. AMPK is a 
heterotrimer composed of one catalytic subunit (AMPK, with two isoforms 1 
and 2), one scaffolding subunit (AMPK, with two isoforms 1 and 2) and a 
regulatory subunit involved in nucleotide binding (AMPK, with three different 
isoforms 1, 2 and 3). The AMPK subunit contains four tandem repeats of a 
structural module called a CBS motif, described initially in the enzyme 
cystathionine--synthase [1], which is involved in AMP, ADP and ATP binding 
[2]. Activation of AMPK is achieved by two complementary mechanisms. On 
one hand, AMPK is allosterically activated by the binding of AMP to the AMPK 
subunit, and on the other hand, the AMPK catalytic subunit is phosphorylated 
in residue Thr172 in the kinase domain by specific upstream kinases (LKB1, 
CaMKK). It has recently been proposed that upon binding of AMP or ADP to 
the AMPK subunit, the AMPK complex undergoes a conformational change 
that makes it a poorer substrate for inactivating dephosphorylation ([3], [4]). 
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Therefore, an AMP/ADP-induced conformational switch and the ensuing 
phosphorylation of the catalytic subunit on Thr172 are the key factors that 
determine the activity of AMPK. The combined action of AMP binding and 
phosphorylation of Thr172 results in a 1,000 fold activation of the AMPK 
complex. Activation of AMPK results in an enhancement of catabolic processes 
and downregulation of anabolic pathways with the aim to equilibrate the energy 
status of the cell. Excellent reviews have been recently published which cover a 
comprehensive view of the importance of AMPK in cell physiology ([5], [6], [7], 
[8], [9]). The involvement of AMPK and AMPK on the regulation of AMPK 
activity has also been recently reviewed ([5], [6], [7], [8], [9]). However, much 
less attention has been paid to the putative function of AMPK subunits on the 
regulation of AMPK function. In this review, we summarize recent reports that 
indicate that AMPK subunits are also critical players in AMPK function. 
Increasing evidence indicate that AMPK subunits regulate the phosphorylation 
status and activity of the AMPK complex and several reports indicate that these 
subunits can be viewed as new targets for therapeutic intervention in the 
development of drugs that activate AMPK complexes containing specific -
isoforms. 
 
1.- Proteins, tissue functions and interacting domains. 
Two isoforms of the AMPK subunit have been described, namely 
AMPK1 and AMPK2. Human AMPK1 is a protein of 270 aa (38 kDa) 
encoded by the PRKAB1 gene, and AMPK2 is a protein of 272 aa (34 kDa) 
encoded by the PRKAB2 gene. They are 71% identical and differ only at the N-
terminus [10]. 
AMPK1 is mainly expressed in liver, pancreas, kidney, brown fat and 
brain, whereas AMPK2 is mainly expressed in cardiac and skeletal muscle 
([10], [11], [12]). The generation of AMPK1 and AMPK2 null mice has 
revealed the distinct action of AMPK complexes containing each subunit in 
different tissues. For example, AMPK1 null mice show a dramatic effect in the 
liver, presenting reduced fasting gluconeogenesis and enhanced hepatic insulin 
sensitivity, what leads them to reduced food intake and body mass, and 
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preserves them from developing high-fat diet induced obesity [13]. AMPK1 null 
mice have also profound brain abnormalities due to reduced AMPK activity in 
this tissue [14]. In addition, the use of AMPK1 null mice has demonstrated a 
critical role of this subunit in controlling AMPK activity in the hypothalamus [13] 
and macrophages [15]. AMPK1-containing complexes play also a role in 
oxidative muscles as soleus, being the expression of AMPK1 dramatically up-
regulated in the absence of endogenous AMPK2 subunit, suggesting that 
AMPK1 subunit can compensate for muscle function in some situations ([16], 
[17]). On the other hand, studies from AMPK2 null mice have demonstrated 
the critical role of AMPK complexes containing this subunit in skeletal muscle 
function, regulating glucose, glycogen and lipid metabolism during metabolic 
stress: AMPK2 null mice show hyperglycemia, glucose intolerance and insulin 
resistance when maintained on a high-fat diet and were unable to maintain 
muscle ATP levels during exercise ([16], [17]). Recently, specific skeletal 
muscle double AMPK12 null mice have been reported. They are physically 
inactive and have impaired contraction-stimulated glucose uptake, 
demonstrating a key role of AMPK in skeletal muscle function [18]. This unique 
tissue specific expression profile of AMPK subunits opens up the possibility of 
designing therapeutic strategies that target functions of AMPK in specific 
tissues. 
AMPKsubunits contain a carbohydrate binding module (CBM) in their 
N-terminal part, which extends from residues 68 to 163. In addition, AMPK 
subunits contain in their C-terminal part [residues 184 to 270 (1)/272 (2)] the 
-SBS (-Subunit Binding Sequence) domain, involved in binding to AMPK 
and AMPK subunits (Fig. 1). 
 
1.1.- Carbohydrate binding module (CBM). 
The CBM found in AMPK subunits is remarkably similar to the major 
carbohydrate binding site of the starch binding domains in cyclodextrin 
glycosyltransferase, -amylase and glucoamylase. Recently, all protein 
modules that bind starch, glycogen or related carbohydrates have been 
classified into different families of carbohydrate binding modules (CBMs). In this 
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classification the CBM of the AMPK subunits now belongs to the CBM48 type, 
found also in amylolytic enzymes from several glycoside hydrolase families [19]. 
These CBMs contain well-conserved consensus residues involved in binding to 
carbohydrate. In the CBM of the AMPK subunits these residues correspond to 
W100, K126 and W133 [19]. These residues were defined previously by 
structural analysis which revealed, in addition, the importance of residues L146 
and N150 in carbohydrate binding [20] (Fig. 1). This study also indicated that 
the CBM adopts a -sandwich fold with a single carbohydrate-binding site 
formed by one of the -sheets and a -hairpin loop (from residues T143 to 
N150; see Fig. 1), that could accommodate five glucosyl units, suggesting that 
malto-pentaose is the smallest oligosaccharide that could prevent 
carbohydrates from binding to AMPK [20]. In agreement with these results, it 
has been recently described that AMPK CBMs bind maltohexose and 
maltoheptaose with a Kd <1 mM, whereas shorter oligosaccharides bind less 
strongly [21]. In addition, this study describes that binding was stronger with 
sugars containing 1-4 with a single glucose 1-6 branch, suggesting that 
AMPK may bind to partially degraded glycogen [21]. 
Among AMPK subunits, the 2 isoform binds carbohydrates more tightly 
than 1, probably as a result of the insertion of a Thr residue (T101) following 
the W100 site involved in carbohydrate binding, which may increase the 
flexibility of the 2-CBM ([22], [23]). This implies that AMPK complexes 
containing 2-subunit could interact with glycogen more efficiently than those 
containing 1-subunit [23]. 
The CBMs of the AMPK subunits are responsible for localizing AMPK to 
glycogen. It has been reported that this polysaccharide can inhibit AMPK 
activity. This regulatory mechanism was first observed in samples from skeletal 
muscle from individuals with high glycogen content which showed a reduced 
activation of AMPK in response to exercise ([24], [25]). Later on, it has been 
demonstrated that addition of glycogen to rat liver AMPK is inhibitory, and that 
this inhibition depends on the presence of the CBM of the -subunit of the 
AMPK complex. Inhibition requires the presence of critical residues in the CBM 
involved in binding to carbohydrates (i.e., W100 and W133) and is mediated by 
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the presence of 1-6 sugar linkages in the carbohydrate molecule (i.e., 
isomaltose but not maltose was inhibitory) [26]. These results led to the 
conclusion that AMPK acts as a cellular glycogen sensor through its CBM-
containing -subunit [26]. However, at present, the molecular mechanism by 
which glycogen inhibits AMPK activity is still unclear. 
The CBM of AMPK subunits seem to be dispensable for the formation 
of a stable heterotrimeric complex since truncated -subunits lacking the entire 
CBM domain still form regular complexes with - and -subunits, which are fully 
active [27]. However, a truncation of the first 65 residues (up to the CBM) [27] or 
the G2A mutant which blocks myristoylation (see below) [28], causes an 
increase in AMPK activity, which suggest that the very N-terminus of AMPK 
subunit either has a direct autoinhibitory role or has a recruiting function of an 
still unknown component to allow autoinhibition indirectly [29]. 
 
1.2.- -Subunit binding sequence (-SBS). 
The -SBS domain is essential for activity. Deletion of small parts of this 
domain leads to forms that can no longer assemble in complexes and are 
inactive, indicating that the -SBS domain is required for the formation of a 
stable, active  complex ([27], [30]). Structural analysis of this domain reveals 
the presence of two -sheets that interact with another -sheet from the N-
terminus of the -subunit ([4], [31]) (Fig. 1 and Fig. 2). In the AMPK1 subunit, 
the C-terminal 85 residues (residues 186-270) are sufficient to form an active 
heterotrimer. The C-terminal 25 residues of 1-subunit (residues 246-270) still 
bind -subunits but not the -subunits and deletion of only the C-terminal Ile270 
precludes association in the absence of -subunit ([32], [33]). The fact that 
only the C-terminal part of the -subunit is involved in binding to the other 
AMPK subunits was confirmed in plants, where it has been found that a new -
subunit isoform (AKIN3), that lacks the N-terminal domain and also the CBM 
domain, is still able to interact with - and -subunits and form an active 
heterotrimeric complex [34]. 
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2.- Structural studies on AMPK subunits when forming part of 
heterotrimeric complex. 
Recent reports on the structure of the heterotrimeric AMPK complex 
indicate that the C-terminus of the -subunit forms a -sheet structure that 
serves as a binding platform for both - and -subunits ([4], [31]). Unfortunately, 
the structure of the other regions of mammalian AMPK subunits has not been 
defined yet. The only available structure containing the CBM domain is the one 
obtained from the Saccharomyces cerevisiae SNF1 complex (yeast orthologue 
of AMPK), containing a C-terminal part of Snf1 (aa 398 to 633) (AMPK 
orthologue), a C-terminal part of Sip2 containing the CBM domain (aa 154 to 
415) (AMPK orthologue) and the full length Snf4 (AMPK orthologue) [35]. In 
this structure, the C-terminal part of the Sip2 protein forms a two -sheets fold 
that interacts with another -sheet from the N-terminus of Snf4. Other regions 
from this C-terminus extend over the C-terminus of the -subunit, although the 
crystal structure of this part is poorly defined. In addition, a clear CBM domain is 
observed, with the carbohydrate binding site facing towards Snf4. In fact, the -
hairpin loop [T143 to N150 (numbers corresponds to residues in AMPK1)] of 
the CBM faces on top of a hydrophobic patch formed by residues I172, F175 
and L178 of the CBS2 of Snf4 (numbers corresponds to residues in AMPK1, 
which has an extra hydrophobic residue Phe179 not present in Snf4) ([29], [31], 
[35]) (Fig. 2). This is particularly interesting since CBS2 participates in the 
formation of site 2 of AMPK subunit, which is empty [31]. The interaction 
between the sugar binding -hairpin loop of the -subunit and the hydrophobic 
patch of the -subunit negatively regulates AMPK activation, since mutation of 
residues in these domains (i.e., F175Y, F175L, F179Y in AMPK1) increase the 
phosphorylation of Thr172 and AMPK activity [29].  
Similar results were obtained in yeast where it was reported that 
mutations in different sites of the -subunit (in this case Gal83, another -
subunit of S. cerevisiae), such as W184A (W100), R214Q (K126) and G235R 
(G147) (in brackets the number of the corresponding residue in AMPK1), 
which affect interactions between residues at the interface of CBM and -
subunit (Snf4 in S. cerevisiae) [35], resulted in increased phosphorylation of 
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Thr210 and catalytic activity [36]. The authors also reported information about 
mutations in residues of the -subunit (Snf4) [C136 (V142), G145 (H151), R169 
(R171) and N177 (F179); in brackets, the conserved residue in AMPK1], all 
located in CBS2, which produce similar enhanced effects on phosphorylation of 
Thr210 and catalytic activity [36]. All these results indicate that AMPK subunit, 
in addition to its function as scaffold to anchor the - and -subunits through the 
-SBS domain, may play an important role in the regulation of the activity of 
the heterotrimeric complex through the interaction of the CBMs with AMPK 
subunit. 
Recently, our group has described that residue G147, in the sugar 
binding -hairpin loop of the -subunit (Fig. 2), participates in binding to R6, a 
regulatory subunit of protein phosphatase 1 (PP1) involved in the glucose-
dependent dephosphorylation and inactivation of AMPK (a G147R mutation 
prevented the interaction of the 1-subunit with R6) [37]. This mutation did not 
affect the interaction between AMPK and AMPK, but diminished its 
interaction with AMPK subunit. These results add an additional role of the 
sugar binding -hairpin loop of the -subunit in the regulation of AMPK activity 
by modulating the binding of specific phosphatases that dephosphorylate and 
inactivate Thr172 within the catalytic subunit. 
 
3.- Posttranslational modifications: 
 The function of AMPK subunits is regulated by different types of 
posttranslational modifications: 
3.1.- Phosphorylation 
AMPK subunits are phosphorylated at multiple sites. In the case of 
AMPK1 this process occurs at Ser24/25, Ser108 and Ser182 (Fig. 1); however 
as AMPK2 lacks the Ser24/25 site, it is only modified in the other two sites 
([28], [38]). Mass spectrometry analysis indicated alternative residues 
phosphorylated in 1 (i.e., Ser96 and Ser101, [39]; Thr80, Thr158, Ser174, 
Ser177 [40]), however no functional studies were presented on the importance 
of these sites on AMPK function. Ser24/25 and Ser108 are autophosphorylated 
by the catalytic activity of AMPK1, whereas Ser182 is phosphorylated by a still 
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unknown upstream kinase. It has been reported that phosphorylation of 
Ser24/25 and Ser182 residues, although it does not affect AMPK activity, is 
necessary for the nuclear exclusion of 1-subunit, whereas phosphorylation of 
Ser108, although it does not affect subcellular distribution of AMPK, increases 
AMPK activity [28]. Interestingly, residue S108 is located in the CBM domain of 
AMPK subunit (Fig. 1), pointing again to the importance of this region in 
regulating the activity of the heterotrimeric complex. 
 
3.2.- Myristoylation 
Myristoylation consists on the addition of myristic acid (a 14 carbon 
saturated fatty acid) to a Gly residue in position 2, following processing of N-
terminal Met residue. The myristoyl group acts as a lipid anchor, recruiting 
modified protein to cellular membranes [41]. Human AMPK subunits contain 
the consensus motif for myristoylation (MGNXXS/T, [42]) as they have at their 
N-terminus the protein sequence MGNTSS (AMPK1) or MGNTTS (AMPK2). 
More importantly, by mass spectrometry analysis it has been demonstrated that 
both AMPK subunits are myristoylated in vivo at Gly2 ([38], [43]). It was also 
reported that the elimination of the myristoylation site (G2A mutant) results in a 
more homogeneous distribution of the AMPK subunits inside the cell and in an 
increase in AMPK activity [28]. To explain this effect, it has been proposed that 
myristoylation may cooperate with the N-terminal first 65 residues of AMPK 
subunits to inhibit AMPK activity. Without myristoylation, the inhibitory effect of 
the N-terminus would be lost, resulting in AMPK activation [28]. 
Recently, it has been reported that myristoylation of AMPK subunits 
increases the ability of AMP to allosterically activate AMPK and to promote 
phosphorylation of the Thr172 site of the catalytic subunit by upstream kinases 
[44]. In addition, these authors indicate that AMP and glucose deprivation 
promote membrane association of myristoylated AMPK, suggesting a 
preferential activation of AMPK at the cellular membrane in response to 
starvation conditions. They also indicate that myristoylation of AMPK subunits 
plays a regulatory function distinct from the classical role in membrane 
association; they suggest that when cellular ATP levels are replete, the 
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myristoyl-group of the -subunit might interact with the AMPK subunit 
suppressing Thr172 phosphorylation and maintaining it in the inactive state. 
Upon a shift to starvation conditions, a myristoyl-switch will occur: the AMPK 
subunit will expose the myristoyl group to the solvent, what would promote 
AMPK membrane association and Thr172 phosphorylation and activation [44]. 
 
3.3.- Ubiquitination 
 This modification consist on the addition of ubiquitin (a 76 amino acid 
protein) moieties to lysine residues of the target protein by a complex 
mechanism that involves the action of a E1-activating enzyme, a E2-conjugating 
enzyme and a E3-ubiquitin ligase, which helps in the transfer of the ubiquitin 
moieties to the target substrate. A single ubiquitin moiety can be attached to the 
target in one (monoubiquitination) o several (multiubiquitination) lysine residues, 
or new ubiquitin moieties can be added to inner lysine residues of the ubiquitin 
molecule (polyubiquitination), forming in this case ubiquitin chains whose 
topology will depend on the lysine residue involved in the modification. As 
ubiquitin contains six lysine residues, chain formation can proceed in any of 
these residues. Depending of the topology of the ubiquitin chains, the modified 
protein will be targeted to destruction by the proteasome (as in the case of K11- 
or K48-linked chains) or will be engaged in non-proteolytical functions (as in the 
case of K63-linked chains) (see [45], for review). In 2008, it was reported that 
AMPK subunits could be modified by ubiquitination [46]. These authors 
demonstrated that the cell-death-inducing DFFA-like effector A (CIDEA), 
promoted the ubiquitination of the C-terminal part of AMPK subunits by an 
unidentified E3-ubiquitin ligase. CIDEA interacted physically with 
AMPKsubunits but not with AMPK or AMPK, and when co-expressed with 
AMPK reduced its stability due to ubiquitin-dependent degradation [46]. 
Consistent with these results CIDEA-/- mice have an enhanced AMPK stability 
and activity, what confirms the hypothesis that CIDEA plays a negative role on 
AMPK activity, likely by targeting the AMPK complex or AMPK subunits for 
degradation by the proteasome [47] (Fig. 3). Although the topology of the 
ubiquitin chains that CIDEA promoted on AMPK was not reported, it is likely 
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that they are of the canonical K48-type, which targets proteins for proteasome-
dependent degradation. 
Our group reported recently the ubiquitination of AMPK subunits by the 
E3-ubiquitin ligase malin [48]. This E3-ubiquitin ligase forms a functional 
complex with laforin, a glucan phosphatase, being both involved in Lafora 
disease, a rare fatal type of progressive myoclonus epilepsy ([49], [50]). The 
topology of the polyubiquitin chain was studied being mainly of the K63-type. 
Perhaps, for this reason, the laforin-malin mediated ubiquitination of AMPK 
subunits did not change their protein stability. On the contrary, this modification 
increased the steady-state levels of AMPK subunits, possibly because it led to 
the accumulation of the proteins into cellular deposits [48]. 
Ubiquitination can be reversed by the action of specific deubiquitinases 
(DUBs), which eliminate ubiquitin moieties from the target protein (see [51] for 
review). In yeast, it has been described that the Ubp8 deubiquitinase mediates 
the deubiquitination of Snf1 (orthologue of AMPK), improving this way the 
stability and phosphorylation status of Snf1 and the activation of SNF1 complex 
activity [51]. On the contrary, deletion of UBP8 gene causes a decrease in 
SNF1 activity, probably due to hyperubiquitination [51]. In addition, it was 
recently described that USP9X deubiquitinase was involved in the 
deubiquitination of AMPK-related kinases NUAK1 and MARK4. USP9X was 
able to remove the atypical K29/K33-kinked ubiquitin chains present in these 
kinases [52]. As deubiquitinases may exhibit ubiquitin linkage specificity [45], it 
remains to be clarified whether USP9X or the mammalian orthologue of Ubp8 
(USP22) might regulate the ubiquitination status of AMPKsubunits. 
Alternatively, other DUBs might be involved in the elimination of the ubiquitin 
chains depending on the corresponding topology (K48-linked, K63-linked) (Fig. 
3). 
 
3.4.- Sumoylation 
Sumoylation consists on the addition of a member of the SUMO (small 
ubiquitin-like modifier) family of ubiquitin-related peptides to lysine residues in 
target proteins, in a process similar to ubiquitination (see [53], and [54] for 
review). In mammals three SUMO paralogues exist: SUMO1, SUMO2 and 
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SUMO3, although SUMO2 and SUMO3 are 96% identical to each other and are 
functionally redundant. The sumoylation reaction requires the participation of 
the E1 SUMO-activating enzyme AOS1/UBA2 and the E2 SUMO-conjugating 
enzyme UBC9/UBE2I. UBC9/UBE2I recognizes a consensus sumoylation motif 
in many known targets (KXD/E, being  any hydrophobic residue and X any 
residue) and although it may interact transiently with target proteins, often the 
efficient conjugation of SUMO moieties requires the participation of an E3 
SUMO-ligase. Similarly to ubiquitination, a single SUMO moiety can be 
attached to the target protein in one (monosumoylation) or several sites 
(multisumoylation), or new SUMO moieties can be attached to inner lysine 
residues of the SUMO molecule (polysumoylation). The latter case is only 
possible with SUMO2/3, since SUMO1 lacks appropriate inner lysine residues. 
For this reason SUMO1 is only able to form monosumoylated derivatives, or it 
can be attached to the end of SUMO2/3 chains (see [53], and [54] for review). 
In contrast to ubiquitination, poly-SUMO modification does not usually trigger 
protein degradation. Instead, sumoylation may affect subcellular localization, 
protein-protein interaction and transcriptional activation of targeted proteins. 
Our group has recently reported that AMPK2 subunit is able to be 
posttranslationally modified by sumoylation [55]. This reaction requires the 
participation of the E3 SUMO-ligase PIASy (protein inhibitor of activated STAT) 
(Fig. 3). AMPK2 interacts physically con PIASy and, as a result of this 
interaction, AMPK2 is modified by the attachment of poly-SUMO2 chains. 
Since in previous results we found a strong yeast two-hybrid interaction 
between AMPK subunits and the E2 SUMO-conjugating enzyme UBC9/UBE2I 
[56], this reinforces our results of AMPK2 being modified by sumoylation. 
Interestingly, AMPK1 is not a target of PIASy, suggesting that the modification 
occurs on lysine residues present in AMPK2 but not in AMPK1. Sumoylation 
of AMPK2 enhances the phosphorylation status of Thr172 in the catalytic 
subunit and the activity of the AMPK complex, probably because this 
modification either improves the phosphorylation of AMPK by upstream kinases 
or because it prevents the dephosphorylation of AMPK by making it a poorer 
substrate for specific phosphatases (Fig. 3). Finally, we also demonstrated that 
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sumoylation and ubiquitination of AMPK2 subunit are competitive and 
antagonistic processes: the promotion of one of the modifications prevents the 
other, and the final consequence of one of them is different from the other: 
sumoylation activates AMPK complex whereas ubiquitination promotes a 
reduction in AMPK activity since it targets AMPK for degradation (Fig. 3). 
Sumoylation is a reversible process. Specific proteases (SENPs, sentrin-
specific proteases) remove the SUMO moieties from target proteins [57] (Fig. 
3). However, at present no information has been reported about the putative 
role of these enzymes in regulating the sumoylation status of AMPK subunits. 
 
4.- Differences between AMPK subunits. 
 Although AMPK1 and AMPK2 are highly similar in protein sequence, 
several reports suggest that each of these subunits can be affected by different 
mechanisms. 
4.1.- Sensitivity to AMPK activators. 
 In 2006, a new activator of AMPK, namely A769622, was described [58]. 
A769622 activates AMPK both allosterically and by inhibiting the 
dephosphorylation of AMPK on Thr172 by specific phosphatases. Its 
mechanism of action does not involve binding to the -subunit, in contrast to 
other AMPK activators (AMP, AICAR, etc.). On the contrary, its effect depends 
on the presence of the -subunit. The CBM of the -subunit plays a key role in 
the mechanism of action of A769622 as its effect is abolished in an AMPK 
complex where the -subunit lacks the carbohydrate binding module. It was 
also reported that A769622 does not interfere with the binding of the CBM to 
carbohydrates and that Ser108 residue plays a role in the activation of AMPK 
by A769622, since a S108A mutation in the -subunit almost completely 
abolishes activation ([29], [59], [60]). As it has been suggested that AMPK 
subunits play a negative role in the regulation of AMPK activity (see above), all 
these results suggest that A769622 acts by reversing the autoinhibitory role of 
the -subunits on AMPK activity. Interestingly, it has been demonstrated that 
A769622 is selective for 1-subunit isoform and does not activate AMPK 
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heterotrimers containing 2-subunits [29]. At present no explanation has been 
proposed for this selective effect of the A769622 compound. 
 A recent study indicates that salicylate activates AMPK through binding 
to the same -subunit site that interacts with A769622. This compound also 
causes allosteric activation and inhibition of the dephosphorylation of the 
Thr172 site in the catalytic subunit on AMPK complexes containing 1, but 
being inactive on 2-containing ones [61]. So, both A769622 and salicylate 
activate AMPK in an AMP-independent manner [62], and their effect depends 
on still unknown modifications in the AMPK1 subunit that avoid the negative 
role that this -subunit has on the activity of the AMPK complex. In the same 
way, GlaxoSmithKline company has recently presented pyrrolo-pyridine 
derivatives with preference for AMPK1 subunit, but again the mechanism of 
action of these compounds is still unknown [63]. 
 
4.2.- Sensitivity to undergo sumoylation 
 As reported above, only AMPK2 can be modified posttranslationally by 
PIASy-dependent sumoylation, leading to the activation of the AMPK complex. 
The basis for this effect is still unknown. Perhaps this modification induces 
changes in the conformation of the -protein that can be transmitted to the 
whole AMPK complex, making it more active. This opens a way to selectively 
activate AMPK complexes containing 2-subunit, as those present in skeletal 
and cardiac muscle. 
 
5.- Concluding remarks 
 Having in mind all the evidence presented in this review, it is clear that 
AMPK subunits have, in addition to their scaffold function in the formation of 
the AMPK complex, alternative functions in the regulation of AMPK activity. 
Mutational analysis of specific residues in the CBS2 domain of AMPK in both 
yeast and mammals and the modification of AMPK subunits, either by 
myristoylation or by mutation of critical residues of the CBM, support the idea 
that AMPK subunits play a critical negative role in the regulation of the activity 
of the AMPK complex. This role may be due, at least in part, to the ability of 
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AMPK subunits to interact with the CBS2 domain of the AMPK subunit. 
Perhaps A769622 and salicylate operate at this interface to activate AMPK 
activity, since they do not affect the binding of AMP to the different AMP-binding 
sites of the AMPK subunit. However, more work needs to be done to 
characterize molecularly the mechanism of action of these compounds. 
Interestingly, AMPK subunits offer selectivity in the activation of the AMPK 
complex. Both A769622 and salicylate are only able to activate 1-containing 
AMPK complexes, whereas sumoylation affects only AMPK complexes 
containing 2-subunit. This selective behavior opens the possibility to design 
specific drugs that may activate one particular type of AMPK complexes in 
specific tissues. 
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FIGURE LEGENDS 
Fig. 1: Structural domains in AMPK subunit. A diagram of human AMPK1 
subunit is shown. The CBM (Carbohydrate Binding Module) (aa 68 to 163) and 
-SBS (-Subunit Binding Sequence) (aa 184 to 270) domains are drawn. 
The position of the myristoylation (G2) and the phosphorylation sites (S24/25, 
S108, S182) is also indicated. On the left, the crystal structure model of CBM 
domain of the rat 1-subunit (residues 68 to 163) (PDB, 1Z0M) [20] was 
modeled using the PyMol programme (DeLano Scientific LLC, San Carlos, CA). 
Residues involved in carbohydrate binding (W100, K126, W133, L146 and 
N150) are colored in green. The position of T143 in the -hairpin loop and S108 
(in red) is indicated. The cyclodextrin ring is also drawn. On the right, the crystal 
structure model of the C-terminus of rat 1-subunit (residues 235 to 270) (PDB, 
4EAK) [4] was also modeled. 
 
Fig. 2: Structure model of the heterotrimeric AMPK complex. On the left, crystal 
structure of the heterotrimeric core of the Saccharomyces cerevisiae SNF1 
complex (PDB, 2QLV) [35] was modeled using the PyMol programme (DeLano 
Scientific LLC, San Carlos, CA). The C-terminal part of Snf1 (AMPK) (residues 
398 to 633) is colored in blue, the C-terminal part of Sip2 (AMPK) (residues 
154 to 415) is colored in green and the full length Snf4 (AMPK) is colored in 
yellow (N-terminus), orange (CBS1), dark brown (CBS2), violet (CBS3) and 
magenta (CBS4). On the right, a zoom of the interface between the - and -
subunits is shown. Residues forming part of the hydrophobic patch [I172 in 
cyan, F175 in blue and L178 in red; numbers correspond to residues present in 
AMPK1, which has in addition a F179 residue (in light blue) instead of Asn] in 
the CBS2 of Snf4, and those forming part of the sugar-binding -hairpin loop of 
Sip2 (T143 to N150, in green; numbers correspond to the residues present in 
AMPK1) are indicated. The position of residue G147 is also indicated. 
 
Fig. 3: Sumoylation and ubiquitination produce antagonist effects of AMPK 
function. AMPK subunits can undergo CIDEA-dependent ubiquitination, 
leading to inhibition of AMPK complex activity, or PIASy-dependent 
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sumoylation, leading to an enhancement of AMPK complex activity. These 
modifications can be reversed by the action of deubiquitinases (DUBs) or 
desumolyases (SENPs) respectively. U, ubiquitin; S, SUMO. 
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